Neurokine Pharmaceuticals Inc.
OTC Bulletin Board : NEUKF

Neurokine Pharmaceuticals Inc.

July 07, 2011 11:23 ET

Neurokine Selects Cognitive Test Protocols for Post CABG Clinical Trials

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 7, 2011) - Neurokine Pharmaceuticals Inc. (the "Company") (OTCBB:NEUKF) is pleased to announce the selection of 11 cognitive battery tests for its coronary artery bypass graft (CABG) neurocognitive impairment clinical trials. These cognitive tests consists of the core battery as defined by an international consensus conference on post CABG cognitive impairment plus others commonly reported tests in the literature. In particular Neurokine will be testing the executive functions of the post CABG patients using:

Rey Auditory Verbal Learning Test
Trail Making A & B
Grooved Pegboard Test
Digit Symbol Substitution Test
Digit Span Forward & Backward
Digit Span Backward
Controlled Oral Word Association Test
Stroop Colour Word Test
Boston Naming Test (30 item short form)
Rey Complex Figure Copy and Immediate Recall

Neurokine's contracted CRO, UK based Clinical Investigations Group, will translate the above language based tests into Romanian and Bulgarian and we will use them in the upcoming Phase II clinical trials scheduled for the Q4 of this year. Management believes that the selection of these tests is a significant milestone in the completion and submission of the post CABG clinical trials protocol in the EU.

About Neurokine: Neurokine Pharmaceuticals Inc. focuses on development of new use for existing marketed products for diseases mediated by acute and chronic inflammatory reactions. The company is developing proprietary encapsulation technology to allow better blood brain barrier penetration to initiate or enhance therapeutic effects of anti-inflammatory drugs in the treatment of neurodegenerative diseases.

Safe Harbor Statement: Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Neurokine or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of Neurokine's products, the competitive environment within the industry, the ability of Neurokine to continue to expand its operations, the level of costs incurred in connection with Neurokine's expansion efforts, economic conditions in the industry and the financial strength of Neurokine's customers and suppliers. Neurokine does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact Information